News for Adicet Bio, Inc. (ACET)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

As of March 31, 2025, ACET reported holding $150.4 million in cash and cash equivalents. This figure reflects a decrease from the $176.3 million recorded at the

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (ACET) CEO, Chen Schor, to join a fireside chat at the 2025 Citizens JMP Life Sciences Conference. The event takes place on May 7, 2025

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (ACET) to present preclinical data on ADI-270 at ASGCT 2025. Presentation to highlight anti-tumor activity compared to conventional CAR

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio (ACET) appoints Michael Grissinger with over 40 years of business development expertise to its Board of Directors. Grissinger brings signific

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. ( HOWL), an innovative biopharmaceutical company pioneering the development of

**media[548365]**

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Julie Maltzman appointed as Chief Medical Officer of Adicet Bio, leading clinical development strategy for autoimmune and oncology pipeline.

Adicet Bio Inc. (ACET) experienced a significant stock price drop of 5.43%, trading at $0.965 per share with a volume of 279,487 shares and a turnover rate of 0